Neisseria meningitidis factor h binding protein
As of the edition of 20 October 2026, Neisseria meningitidis factor h binding protein is a vaccine component: marketed, first approved in 2014 (US); US protection ends in 2026.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2014
- Kind
- Vaccine component
- Brand name
- Trumenba
- First approved
- 29 October 2014 (US)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Pfizer
- Registered trials
- 5, 0 stopped early
- Disease areas
- Blood and lymph; Immune system; Inherited and neonatal
US protection
US protection ends in 2026.
The reference-product exclusivity ends in 2026. The application that gives this date is held by Pfizer.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product1 listing counts towards this date. The exact date and each listing are in the product.
See the exact date and the 1 listing behind itRequest access. Nothing is shown until you do.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 3 | 3 | 2 | 1 | 0 |
| Phase 4 | 2 | 1 | 1 | 0 |
| All trials | 5 |